Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228
Paul K. Paik(Memorial Sloan Kettering Cancer Center), Charles M. Rudin(Memorial Sloan Kettering Cancer Center)
Cited by 35
Related Papers
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
|New England Journal of Medicine|2009|1k
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations
|Journal of Clinical Oncology|2011|689
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
|Frontiers in Oncology|2020|112
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
|Journal of Hematology & Oncology|2021|92
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
|Science Translational Medicine|2023|44